Difficulties in the pooled platelets implementation: 616.411-003.971

Abstract

Summary. Background. The improvement of blood service technologies has formed the conditions for collection of pooled platelets isolated from whole blood. In fact, pooled platelets are obtained from whole blood processing waste, which significantly reduces the cost of this full-fledged therapeutic product. Objective: to identify difficulties in the implementation of pooled platelet concen- trates both at the stage of collection and clinical use. Materials/Methods. Using the two-stage Delphi method, at the first stage, 85 experts identified the difficulties of introducing pooled platelets; at the second stage, 50 experts accessed their significance on a 10-point scale. Results. It is difficult to obtain pooled platelets with a daily small number of donors. This difficulty is solved by centralizing blood processing in the region or by transferring buffy coats to the regional blood transfusion station. The slow work of the laboratory complicates platelet pooling. In such organizations, blood components are dispensed with a delay, which worsens the functional state of blood elements, primarily platelets. The main problem for the introduction of pooled platelet transfusion into the clinic, the participants of the study consider the lack of knowledge about the benefits of this blood compo- nent. The apheresis machine effect on platelets is greater than with pooling. The quality parameters at the end of the storage period of pooled leukodepleted platelets in an additional solution are better than those of apheresis ones. Conclusions. Thus, the main difficulty for the procurement of pooled platelet concentrates is the small number of donors who visit the donor center daily. A possible solution is to transfer all buffy coats received in the region to a single center for pooled platelets preparation. Such centralization of donor laboratory examination will allow quickly get the result and, reducing unproductive storage quickly release platelets into the clinic. Updating of knowledge, continuous medical education of transfusiologists and clinical depart- ments physicians will serve the further introduction of leukodepleted pathogen-reduced pooled platelet concentrate in an additive solution — a modern, effective and safe product for thrombocytopenia correction.

For citation: Khamitov R.G., Gavriley A.V., Drozhzhina I.E., Kostikova O.N., Kochetkova M.A., Medyantseva L.G., Rassokhina O.I., Taskaeva E.I., Shestakov E. .A., ZhiburtE.B. Difficulties in the pooled platelets implementation. Tromboz, gemostaz i reologiya. 2022;(4):22–29. (In Russ.).

References

1. Madzaev S.R., Gubanova M.N., Burkitbaev Zh.K. et al. New in evidence-based platelets trnsfusion. Vestnik Nacional’nogo medikohirurgicheskogo centra imeni N.I. Pirogova. 2013;8(4):57–8. (In Russ.).
2. Kuznetsov S. I., Abdrakhmanova S. A., Burlaeva E. M. et al. Pooled platelets obtaining from whole blood. Transfuziologiya. 2020;21(2):108–14. (In Russ.).
3. Roitman E.V., Kolesnikova I.M., Karpova O.V. et al. The study of relationship between platelet metabolic activity and platelet hemostatic properties during the storage of platelet concentrates produced by different methods. Tromboz, gemostaz i reologiya. 2016;(3):48–55. (In Russ.).
4. Kolesnikova I.M., Roitman E.V., Pechennikov V.M., Kostin A.I. Blood clot properties appearing after transfusion reflect hemostatic quality of platelet concentrates. Tromboz, gemostaz i reologiya. 2017;(4):75–81. (In Russ.). DOI: 10.25555/THR.2017.4.0814.
5. Protopopova E.B., Mochkin N.E., Shestakov E.A. et al. Neutropenia and platelet transfusion at autologous stem cell transplantation. Tromboz, gemostaz i reologiya. 2016;(1):72–6. (In Russ.).
6. Ayupova R.F., Sultanbaev U.S., Zhiburt E.B. Effectiveness of single and double doses platelet transfusions. Tromboz, gemostaz i reologiya. 2017;(2):19–22. (In Russ.). DOI: 10.25555/THR.2017.2.0779.
7. Tankaeva Kh.S., Shestakov E. A., Melnichenko V. Ya., Zhiburt E.B. Is group O platelet hemostatic activity reduced? Tromboz, gemostaz i reologiya. 2020;(3):75–8. (In Russ.). DOI: 10.25555/ THR.2020.3.0932.
8. Gubanova M.N., Protopopova E.B., Zarubin M.N. et al. Polymorphism of preparation, transfusion and effectiveness of donor platelets concentrates. Tromboz, gemostaz i reologiya. 2016;(S3):136– 7. (In Russ.).
9. Berger K., Schopohl D., Wittmann G. et al. Blood product supply in Germany: the impact of apheresis and pooled platelet concentrates. Transfus Med Hemother. 2016;43(6):389–94. DOI: 10.1159/000445442.
10. Madzaev S.R., Belskaya T.E., Vafin I.A. et al. Three problems of blood service efficiency. The Delphi method. Transfuziologiya. 2013;14(4):57–64. (In Russ.).
11. Chemodanov I.G., Averyanov E.G., Ayupova R.F. et al. Improvement order of blood donar re-entry. Transfuziologiya. 2018;19(2):17– 24. (In Russ.).
12. Kuznetsov S.I., Averyanov E.G., Khamitov R.G. et al. Controversial and indisputable in the recommendations for the red blood cell transfusion. Transfuziologiya. 2020;21(2):161–76. (In Russ.).
13. Kuznetsov S.I., Averyanov E.G., Davydova L.E. et al. Controversial and indisputable in recommendations for the cryoprecipitate transfusion. Transfuziologiya.2020;21(3):269–78. (In Russ.).
14. Kuznetsov S.I., Averyanov E.G., Davydova L.E. et al. Controversial and indisputable in recommendations for the cryosupernatant plasma transfusion. Transfuziologiya. 2021;22(2):179–87. (In Russ.).
15. Zabolotskikh I.B., Grigoryev S.V., Belkin A.A. et al. Consensus technologies in the analysis of guidelines: international experience of application of Delphi method in anesthesiology and intensive care. Systematic review. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2021;(1):90–106. (In Russ.). DOI: 10.21320/1818474X-2021-1-90-106.
16. Zarubin M.V., Gubanova M.N., Gaponova T.V. et al. Efficiency and safety of platelet transfusion. Vestnik Nacional’nogo mediko-hirurgicheskogo centra imeni N.I. Pirogova. 2016;11(3):118–25. (In Russ.).
17. Protopopova E.B., Mochkin N.E., Melnichenko V. Ya. et al. Shelf life affects the effectiveness of platelet transfusion. Transfuziologiya. 2016;17(1):37–48. (In Russ.).
18. Zhiburt E.B. Management patient’s blood at critical bleeding and massive transfusion. Vestnik Nacional’nogo mediko-hirurgicheskogo centra imeni N.I. Pirogova. 2013;8(4):71–7. (In Russ.).
19. Cardigan R., New H.V., Estcourt L. et al. International forum on policies and practice for transfusion of ABO and RhD non-identical platelets: summary. Vox Sang. 2022;117(1):136–44. DOI: 10.1111/ vox.13129.
20. Shevchenko Yu.L., Karpov O.E., Zhiburt E.B. Blood transfusion: history and modernity (to the 100th anniversary of blood transfusion in Russia). Vestnik Nacional’nogo mediko-hirurgicheskogo centra imeni N.I. Pirogova. 2019;14(4):4–11. (In Russ.). DOI: 10.25881/ BPNMSC.2020.29.78.001.
21. Kumar R., Dhawan H.K., Sharma R.R., Kaur J. Buffy coat pooled platelet concentrate: A new age platelet component. Asian J Transfus Sci. 2021;15(2):125–32. DOI: 10.4103/ajts.AJTS_72_19.
22. Chu Y.-H., Rose W.N., Nawrot W., Raife T.J. Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology. J Int Med Res. 2021;49(5):3000605211016748. DOI: 10.1177/03000605211016748. Daurat A., Roger C., Gris J. et al. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data. Transfusion. 2016;56(6):1295–303. DOI: 10.1111/ trf.13475.
23. Mowla S.J., Kracalik I.T., Sapiano M.R.P. et al. A comparison of transfusion-related adverse reactions among apheresis platelets, whole blood-derived platelets, and platelets subjected to pathogen reduction technology as reported to the National Healthcare Safety Network Hemovigilance Module. Transfus Med Rev. 2021;35(2):78–84. DOI: 10.1016/j.tmrv.2021.03.003.
24. Gammon R., Cook S., Trinkle A. et al. Acute hemolytic transfusion reaction due to pooled platelets: a rare but serious adverse event. Lab Med. 2021;52(2):202–4. DOI: 10.1093/labmed/lmaa056. Cooling L.L., Downs T.A., Butch S.H., Davenport R.D. Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets. Transfusion. 2008;48(10):2106–13. DOI: 10.1111/j.1537– 2995.2008.01814.x. PMID: 18631162.
25. Pietersz R.N. Pooled platelet concentrates: an alternative to single donor apheresis platelets? Transfus Apher Sci. 2009;41(2):115– 9. DOI: 10.1016/j.transci.2009.07.003.
26. Vamvakas E.C. The ethics of wasting the donor’s gift of buffy coat. Vox Sang. 2011;100(2):256–9. DOI: 10.1111/j.1423–0410.2010.01405.x. Чемоданов И.Г., Аверьянов Е.Г., Кузнецов С.И. и др. Гемонадзор в Великобритании. Трансфузиология. 2020;21(1):68–78. Chemodanov I.G., Averyanov E.G., Kuznetsov S.I. et al. Hemovigilance in the UK. Transfuziologiya. 2020;21(1):68–78. (In Russ.).